Moxidectin

Drug Profile

Moxidectin

Alternative Names: Milbemycin B

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Developer Medicines Development Limited; Pfizer; World Health Organization
  • Class Anthelmintics; Macrolides; Small molecules
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Onchocerciasis

Most Recent Events

  • 01 May 2017 Medicines Development completes a phase I trial in Onchocerciasis (In volunteers) in USA (PO) (NCT03012828)
  • 01 Jan 2017 Phase-I clinical trials in Onchocerciasis (In volunteers) in USA (PO) (NCT03012828)
  • 11 Aug 2011 Discontinued - Phase-III for Onchocerciasis in Congo (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top